Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Johnson and Johnson
AstraZeneca
Medtronic
Baxter

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,076,514

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,076,514 protect, and when does it expire?

Patent 10,076,514 protects GALAFOLD and is included in one NDA.

This patent has ten patent family members in six countries.

Summary for Patent: 10,076,514
Title:Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing .alpha.-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for .alpha.-galactosidase A, wherein the patient has a splice site mutation in intron 4 of the nucleic acid sequence encoding .alpha.-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.
Inventor(s): Benjamin; Elfrida (Millstone Township, NJ)
Assignee: Amicus Therapeutics, Inc. (Cranbury, NJ)
Application Number:15/459,149
Patent Claim Types:
see list of patent claims
 

Drugs Protected by US Patent 10,076,514

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amicus Theraps Us GALAFOLD migalastat hydrochloride CAPSULE;ORAL 208623-001 Aug 10, 2018 RX Yes Yes   Start Trial   Start Trial THE TREATMENT OF FABRY PATIENTS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,076,514

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 109069494   Start Trial
European Patent Office 3432882   Start Trial
Japan 2019510030   Start Trial
South Korea 102004114   Start Trial
South Korea 20180119691   Start Trial
South Korea 20190087673   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Medtronic
Boehringer Ingelheim
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.